Bicalutamide Teva 50 mg Норвешка - Норвешки - Statens legemiddelverk

bicalutamide teva 50 mg

teva sweden ab - bikalutamid - tablett, filmdrasjert - 50 mg

Nebido 1000 mg/4 ml Норвешка - Норвешки - Statens legemiddelverk

nebido 1000 mg/4 ml

paranova as (1) - testosteronundekanoat - injeksjonsvæske, oppløsning - 1000 mg/4 ml

Casodex 150 mg Норвешка - Норвешки - Statens legemiddelverk

casodex 150 mg

laboratoires juvisé pharmaceuticals - bikalutamid - tablett, filmdrasjert - 150 mg

Casodex 50 mg Норвешка - Норвешки - Statens legemiddelverk

casodex 50 mg

laboratoires juvisé pharmaceuticals - bikalutamid - tablett, filmdrasjert - 50 mg

Leuprorelin Sandoz 5 mg Норвешка - Норвешки - Statens legemiddelverk

leuprorelin sandoz 5 mg

sandoz - københavn - leuprorelinacetat - implantat - 5 mg

Flutamid Orion 250 mg Норвешка - Норвешки - Statens legemiddelverk

flutamid orion 250 mg

orion corporation orion pharma - flutamid - tablett - 250 mg

Bicalutamide Bluefish 50 mg Норвешка - Норвешки - Statens legemiddelverk

bicalutamide bluefish 50 mg

bluefish pharmaceuticals ab - bikalutamid - tablett, filmdrasjert - 50 mg

Bicalutamide Teva 150 mg Норвешка - Норвешки - Statens legemiddelverk

bicalutamide teva 150 mg

teva sweden ab - bikalutamid - tablett, filmdrasjert - 150 mg

Firmagon Европска Унија - Норвешки - EMA (European Medicines Agency)

firmagon

ferring pharmaceuticals a/s - degarelix - prostata neoplasmer - endokrin terapi - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Degarelix Accord Европска Унија - Норвешки - EMA (European Medicines Agency)

degarelix accord

accord healthcare s.l.u. - degarelix acetate - prostata neoplasmer - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.